Cutaneous reactions after SARS-CoV-2 vaccination: a cross-sectional Spanish nationwide study of 405 cases
-
- A. Català
- Servicio de Dermatología Hospital Clínic Barcelona Spain
-
- C. Muñoz-Santos
- Servicio de Dermatología Hospital General de Granollers Barcelona Spain
-
- C. Galván-Casas
- Servicio de Dermatología Hospital Universitario de Móstoles Madrid Spain
-
- M. Roncero Riesco
- Servicio de Dermatología Complejo Asistencial Universitario de Salamanca Salamanca Spain
-
- D. Revilla Nebreda
- Servicio de Dermatología Complejo Asistencial Universitario de Salamanca Salamanca Spain
-
- A. Solá-Truyols
- Servicio de Dermatología Hospital Universitario Son Llatzer Mallorca Spain
-
- P. Giavedoni
- Servicio de Dermatología Hospital Clínic Barcelona Spain
-
- M. Llamas-Velasco
- Servicio de Dermatología Hospital Universitario de La Princesa Madrid Spain
-
- C. González-Cruz
- Servicio de Dermatología Hospital Universitari Vall D’Hebron Barcelona Spain
-
- X. Cubiró
- Servicio de Dermatología Hospital de la Santa Creu i Sant Pau Barcelona Spain
-
- R. Ruíz-Villaverde
- Servicio de Dermatología Hospital Universitario San Cecilio Granada Spain
-
- S. Gómez-Armayones
- Servicio de Dermatología Hospital Clínic Barcelona Spain
-
- M.P. Gil Mateo
- Servicio de Dermatología Hospital General de La Palma Santa Cruz de Tenerife Spain
-
- D. Pesqué
- Servicio de Dermatología Hospital del Mar IMIM Universitat Autònoma Barcelona Spain
-
- O. Marcantonio
- Servicio de Dermatología Hospital del Mar IMIM Universitat Autònoma Barcelona Spain
-
- D. Fernández-Nieto
- Servicio de Dermatología Hospital Ramón y Cajal Madrid Spain
-
- J. Romaní
- Servicio de Dermatología Parc Taulí Hospital Universitari Sabadell, Barcelona Spain
-
- N. Iglesias Pena
- Servicio de Dermatología Hospital Universitario Lucus Augusti Lugo Spain
-
- L. Carnero Gonzalez
- Servicio de Dermatología Hospital Universitario Araba Vitoria Spain
-
- J. Tercedor-Sanchez
- Servicio de Dermatología Hospital Virgen de las Nieves Granada Spain
-
- G. Carretero
- Servicio de Dermatología Hospital Universitario Gran Canaria Doctor Negrín Las Palmas Gran Canaria Spain
-
- T. Masat-Ticó
- CAP Cardedeu Institut Català de la Salut Barcelona Spain
-
- P. Rodríguez-Jiménez
- Servicio de Dermatología Hospital Universitario de La Princesa Madrid Spain
-
- A.M. Gimenez-Arnau
- Servicio de Dermatología Hospital del Mar IMIM Universitat Autònoma Barcelona Spain
-
- M. Utrera-Busquets
- Servicio de Dermatología Hospital Comarcal Infanta Elena Huelva Spain
-
- E. Vargas Laguna
- Servicio de Dermatología Hospital Universitario Severo Ochoa Madrid Spain
-
- A.G. Angulo Menéndez
- Servicio de Dermatología Serveis Medics Penedés Vilanova i la Geltrú Barcelona Spain
-
- E. San Juan Lasser
- Consulta privada Dra Eliana San Juan Lasser Madrid Spain
-
- M. Iglesias-Sancho
- Servicio de Dermatología Hospital Universitari Sagrat Cor Barcelona Spain
-
- L. Alonso Naranjo
- Servicio de Dermatología Hospital Universitario de Toledo Toledo Spain
-
- I. Hiltun
- Servicio de Dermatología Complejo Hospitalario de Navarra Navarra Spain
-
- E. Cutillas Marco
- Servicio de Dermatología Hospital General Universitario Reina Sofia Murcia Spain
-
- I. Polimon Olabarrieta
- Servicio de Dermatología Hospital Universitario de Móstoles Madrid Spain
-
- S. Marinero Escobedo
- Servicio de Dermatología Hospital Universitario de Móstoles Madrid Spain
-
- X. García-Navarro
- Servicio de Dermatología Consorci Sanitari Alt Penedès-Garraf Barcelona Spain
-
- M.J. Calderón Gutiérrez
- Consulta Privada María José Calderón Bilbao Spain
-
- G. Baeza-Hernández
- Servicio de Dermatología Hospital Universitario de Fuenlabrada Madrid Spain
-
- L. Bou Camps
- Consulta Dr Lola Bou Barcelona Spain
-
- T. Toledo-Pastrana
- Hospital Quirónsalud Infanta Luisa Sevilla Spain
-
- A. Guilabert
- Servicio de Dermatología Hospital General de Granollers Barcelona Spain
抄録
<jats:title>Summary</jats:title> <jats:p>Background</jats:p> <jats:p>Cutaneous reactions after severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) vaccines are poorly characterized.</jats:p> <jats:p>Objective</jats:p> <jats:p>To describe and classify cutaneous reactions after SARS-CoV-2 vaccination.</jats:p> <jats:p>Methods</jats:p> <jats:p>A nationwide Spanish cross-sectional study was conducted. We included patients with cutaneous reactions within 21 days of any dose of the approved vaccines at the time of the study. After a face-to-face visit with a dermatologist, information on cutaneous reactions was collected via an online professional survey and clinical photographs were sent by email. Investigators searched for consensus on clinical patterns and classification.</jats:p> <jats:p>Results</jats:p> <jats:p>From 16 February to 15 May 2021, we collected 405 reactions after vaccination with the BNT162b2 (Pfizer-BioNTech; 40·2%), mRNA-1273 (Moderna; 36·3%) and AZD1222 (AstraZeneca; 23·5%) vaccines. Mean patient age was 50·7 years and 80·2% were female. Cutaneous reactions were classified as injection site (‘COVID arm’, 32·1%), urticaria (14·6%), morbilliform (8·9%), papulovesicular (6·4%), pityriasis rosea-like (4·9%) and purpuric (4%) reactions. Varicella zoster and herpes simplex virus reactivations accounted for 13·8% of reactions. The COVID arm was almost exclusive to women (95·4%). The most reported reactions in each vaccine group were COVID arm (mRNA-1273, Moderna, 61·9%), varicella zoster virus reactivation (BNT162b2, Pfizer-BioNTech, 17·2%) and urticaria (AZD1222, AstraZeneca, 21·1%). Most reactions to the mRNA-1273 (Moderna) vaccine were described in women (90·5%). Eighty reactions (21%) were classified as severe/very severe and 81% required treatment.</jats:p> <jats:p>Conclusions</jats:p> <jats:p>Cutaneous reactions after SARS-CoV-2 vaccination are heterogeneous. Most are mild-to-moderate and self-limiting, although severe/very severe reactions are reported. Knowledge of these reactions during mass vaccination may help healthcare professionals and reassure patients.</jats:p>
収録刊行物
-
- British Journal of Dermatology
-
British Journal of Dermatology 186 (1), 142-152, 2022-01-01
Oxford University Press (OUP)